Genentech Backtracks In Synagis Dispute

Law360, New York (November 2, 2006, 12:00 AM EST) -- Genentech Inc. has pulled a complaint against biotech competitor MedImmune Inc. which alleged that MedImmune’s Synagis, used to stave off dangerous respiratory tract infections in infants, violated its patents.

As it wrangles with Genentech over a patent-license dispute over the same product before the U.S. Supreme Court, MedImmune said it had never received this complaint, according to a filing with the U.S. Securities and Exchange Commission on Wednesday. Genentech filed the complaint in January in the U.S. District Court for the Eastern District of Texas....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.